Mesoblast (ASX:MSB, NASDAQ:MESO)
Mesoblast is posting phase 3 COVID-19 trial in about 1-2 months. No interim analysis so far means the drug is efficacious enough to continue. Positive results could see the first viable COVID-19 treatment for the cytokine storm. Definitely, a COVID-19 biotech bang buster to watch.